Controlled release systems and low dose androgens

Details Controlled release systems and low dose androgens Controlled release systems and low dose androgens

1995-03-03

1997-05-13

Nutter, Nathan M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514170, 514177, 514179, A01N 4500, A61K 3156

Patent

active

056293038

ABSTRACT:
Methods of treatment and prevention of estrogen-related diseases, and of fertility control, include low dose (e.g. less than 50 nanomolar serum concentration)administration of certain anabolic steroids, progestins and other substantially non-masculinizing androgenic compounds. Sustained release formulations substantially free of organic solvent, and sustained release formulations for maintaining low serum levels of androgen are disclosed.

REFERENCES:
patent: 3773919 (1973-11-01), Boswell
patent: 4071622 (1978-01-01), Johnson
patent: 4107071 (1978-08-01), Bayless
patent: 4166800 (1979-09-01), Fong
patent: 4472382 (1989-09-01), Labrie
patent: 4522831 (1985-06-01), Chatterton, Jr.
patent: 4624665 (1986-11-01), Nuwayser
patent: 4659695 (1987-04-01), Labrie
patent: 4760053 (1988-07-01), Labrie
patent: 4775660 (1988-10-01), Labrie
patent: 4775661 (1988-10-01), Labrie
patent: 4818542 (1989-04-01), DeLuca
patent: 4826831 (1989-05-01), Plunkett
patent: 4863744 (1989-09-01), Urquhart
patent: 4987268 (1991-01-01), Rauleder
patent: 5023080 (1991-06-01), Gupta
patent: 5043331 (1992-08-01), Hirvonen
patent: 5362720 (1994-11-01), Labrie
Albright, et al., In: The Parathyroid Glands & Metabolic Bone Disease, Williams & Williams Co: Baltimore, pp. 145-204 (1948).
Aloia et al., Metabolism 30:1076-1079 (1981).
Asselin et al., Cancer Res. 40:1612-1622 (1980).
Baran et al., Calif. Tissue Res. 26:103-106, 1978.
Bryan et al., Cancer 54: 2436-2440, 1984.
Bullock et al., Endocrinology 103: 1768-1782, 1978.
Chessnut et al, Metabolism 26: 267-277, 1977.
Chessnut et al. Metabolism 32:571-580, 1983.
Clavel et al., Eur J. Cancer Clin. Oncol. 18:821-826, 1982.
Cooperative Breast Cancer Group, JAMA 188, 1069-1072, 1964.
Cremonicini et al., Acta. Eur. Fertil. 7:248-314, 1976.
Cusan et al., J. Am. Acad. Dermatol. 23:462-469, 1990.
Dauvois & Labrie, Cancer Res. 51:3131-3151 (1991).
Dauvois, et al., Breast Cancer. Res. Treatment 14:299-306 (1989).
Dequaker & Geusens, Acta Endocrimol 271 (Suppl): 45-52, 1985.
Dhem, A., Ars-Piret N., Waterschoot MP (1980) Curr. Med. Res. Opin. 6: 606-613.
Dickson & Lippman, Endocr. Rev. 8:29-43, 1987.
Dixon et al., Clinical Endocrinology 30: 271-277, 1989.
Earl et al., Clin. Oncol. 10:103-109, 1984.
Engel et al., Cancer Res. 38: 3352-3364, 1978.
Engelsman et al., British J. Cancer 30: 177-181, 1975.
Ferriman & Gallwey, J.P. Clin Endocrimol. Metab 21: 1440-1447, 1961.
Finkelstein et al., J. Clin. Endocr. Metab. 69:776-783, 1989.
Francis, et al., Bone 7: 261-268 (1986).
Foresta et al., Horm. Metab. Res. 15:206-207, 1983.
Foresta et al., Horm. Metab. Res. 15:56-57, 1983.
Goldenberg et al., JAMA 223: 1267-1268, 1973.
Greenspan et al., Ann. Int. Med. 110:526-531, 1989.
Greenspan et al., Ann. Int. Med. 104:777-782, 1986.
Harrison et al., Metabolism 20:1107-1118, 1971.
Hollo et al., Lancet 2:1205, 1971.
Hilf. R., Anabolic-Androgenic Steroids and Experimental Tumors In: Handbook of Experimental Pharmacology, vol. 43, Anabolic-Androgenic Steroids, Springer-Verlag, Berlin 43 (1976) 191-210 and p., 725.
Johnson et al. Semin. Oncol. 13(suppl):15-19, 1986.
Kennedy et al., Cancer 21: 197-201, 1970.
Kennedy, Hormone Therapy in Cancer Geriatrics 25: 106-112, 1970.
Klijn et al., J. Steroid Biochem. 20: 1381, 1984.
Krabbe et al., Arch. Dis. Child, 54, 950-953, 1979.
Krabbe et al., Arch. Pediat. Scand. 73:750-755, 1984.
Labrie, et al., Fertil. Steril. 31:29-34, 1979.
Lafferty et al., Ann. J. Med. 36: 514-528, 1964.
Lamb, Am. J. Sports Medicine 121, 31-38, 1984.
Lippman et al., Cancer 38: 868-874, 1976.
Lucas, Obstet. Gynecol. Surv. 29: 507-528, 1974.
Luthy et al., J. Steroid Biochem. 31: 845-852, 1988.
Mack et al., N. Engl. J. Medicine 294: 1262-1267, 1976.
Manni et al., Cancer 48: 2507-2509, 1981.
Manni et al., Endocr., Rev. 7: 89-94 (1986).
McDermott & Kidd, End. Rev. 8:377-390, 1987.
Miller et al., Eur. J. Oncol. 21: 539-542, 1985.
Need et al., Mineral Electrolyte Metabolism 11:35, 1985.
Nicholson et al., J. Steroid Biochem. 23: 843-848, 1985.
Nicholson et al., Brit. J. Cancer 39: 268-273, 1979.
Ogata et al., Endocrinology 87:421, 1970.
Plante et al., J. Steroid Biochem. 31: 61-64, 1988.
Poulin et al., Breast Cancer Res. Treatment 13:265-276, 1989.
Poyet and Labrie, Mol. Cell Endocrinol. 42: 283-288, 1985.
Poyet, et al., The Prostate 9: 237-246, 1986.
Puche & Rosmano, Calif. Tissue Res. 4:39-47, 1969.
Raynaud et al. Steroid Hormones, Agonists and Antagonists In: Mechanisms of Steroid Action, MacMillan Press, London, pp. 143-157 (1981).
Raynaud & Ojasso In: Innovative Approaches in Drug Research, Elsevier Sci. Publishers, Amsterdam, pp. 47-72, 1986.
Raynaud & Ojasso, J. Sterod Biochem. 25:811-833, 1986.
Rendina et al., Europ. J. Obstet Gynecol. Reprod. Biol. 17: 285-291, 1984.
Riggs et al., J. Clin. Invest. 67:328-335, 1987.
Riggs et al., J. Clin. Invest. 51:2659-2663, 1972.
Rigotti et al. JAMA 256:385-288, 1986.
Riis et al., Calif. Tissue Res. 37:213-217, 1985.
Rochefort and Chalbos, Mol. Cell Endocrinol. 36: 3-10, 1984.
Rodbard, Endocrinology 94:1427-1437, 1974.
Sandberg and Kirdoni, Pharmac.Ther. 36:263-307, 1988.
Saville Clin. End. Metab. 2:177-185 (1973).
Seeman et al., Am. J. Medicine 75:977-983, 1983.
Selbey et al., Clin. Sci. 69:265-271, 1985.
Simard et al., Mol. Endocrinol, 3:694-702, 1984.
Simard et al., Endocrinology 126:3223-3231, 1990.
Smith et al., N.Engl. J. Medicine 293: 1164-1167, 1975.
Smith and Walker, Calif. Tissue Res. 22 (Suppl.):225-228, 1976.
Tchekmedyan et al., Semin. Oncol. 13(Suppl):20-25, 1986.
Telimaa et al., Gynecol. Endocrinol. 1:13, 1987.
Teulings et al., Cancer Res. 40: 2557-2561, 1980.
Tormey et al., Ann. Int. Med. 98: 139-144, 1983.
Toth & Zakar J.Steroid Biochem 17:653-660, 1982.
Tseng and Gurpide, J. Clin. Endocrinol. Metab. 41, 402-404, 1975.
Van Veelen et al., Cancer 58, 7-13, 1986.
Van Veelen et al., Cancer Treatment Rep. 69: 977-983, 1985.
Velentzas & Karras, Nouv. Presse Medicale 10: 2520, 1981.
Vignon et al., J. Clin Endocrinol Metab. 56: 1124-1130, 1983.
Webster & Hogkins, Proc. Soc. Exp. Biol. Med. 72-75, 1940.
Vincens et al., Les Androgenes In: Pharmacologie Clinique Base de Therapeutique, 2ieme Ed., Expansion Scientific (Paris),pp. 2139-2158, 1988.
Wilson & Griffin, Metabolism 28:1278, 1980.
Witcliff, Cancer 53: 630-643,, 1984.
Witcliff, In: Bush, H. (Ed.), Methods in Cancer Res., No.11, Acad. Press, New York, 1975 pp. 293-304.
Chem. Abstr. 97(4):28542e (Jul. 26, 1982).
The Merck Index No. 5677, p. 909; No. 5687, p. 910 (1989).
The Merck Index No. 7486, p. 1188 Pizotyline (1989).
Wink and Felts, Calcif. Tissue Res. 32:77-82 (1986).
Wise, et al., Biology and Medicine pp. 237-270 (1979).
Adair, et al., Ann. Surg. 123:1023-1035 (1946).
Adair, et al., JAMA 140:1193-2000 (1949).
Adair, Surg. Gynecol. Obstet. 84:719-722 (1947).
Allegra et al., Cancer Res. 39:1447-1454 (1979).
Aloia et al., Arch. Int. Med. 143:1700-1704 (1983).
Anderson, et al., Contraception 13:375-394 (1976).
Baker (1987) Controlled release of biologically active agents.
Beck, et al., Adv. in Human Fert. & Reprod. Endo., pp. 175-199 (1983).
Blossey et al., Cancer 54:1208-1215 (1984).
Blumenschein, Semin. Oncol. 10:7-10 (1983).
Centola, Cancer Res. 45:6264-6267 (1985).
Colvard, et al., Proc. Natl. Acad. Sci. 86:854-857 (1989).
Deutsch et al., Int. J. Gynecol. Obstet. 25:217-222 (1987).
Ehrlich et al., Am. J. Obstet Gynecol. 158:796-807 (1988).
Eriksen et al., Science 241:84-86 (1988).
Finkelstein et al., Ann. Int. Med. 106:354-361 (1987).
Gresser, et al., Contraception 17:253-267 (1978).
Hall, Fertility Regulation, Today and Tomorrow pp. 119-141 (1987).
Haller and Glick, Semin. Oncol. 13:2-8 (1986).
Hamblen, South Med. J. 50:743-750 (1987).
Hollo and Feher, Acta. Med. Hung. 20:233-247 (1964).
Hollo et al., Acta Med. Hung. 27:155-160 (1970).
Hollo et al., Lancet 1:1357 (1976).
Hortobagyi et al., Breast Cancer Res. Treatm. 5:321-326 (1985).
Horwitz, J. Steroid Biochem. 27:447-457 (1987).
Horwitz et al., Cancer Res. 38:2434-2439 (1978).
Kitchell, et al., Methods in Enzymology 112:436-448 (1985).
Komm, et al., Science 241:81-84 (1988).
Kramer, Biometrics 12:307-310 (1956).
Labrie, et al., J. St

Affiliated with

Also associated with

Rating

Controlled release systems and low dose androgens does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Controlled release systems and low dose androgens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release systems and low dose androgens will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1385495